IT 349
Education
- Ph.D. in Biomedical Engineering, University of Michigan
- Master of Science in Biomedical Engineering, University of Michigan
- Bachelor of Science in Civil Engineering, National Taiwan University
Biography
Chia-Ying (James) Lin, PhD is currently the Inaugural Executive Director of the Convergent Bioscience and Technology Institute at Indiana University (IU) Indianapolis, and also a professor of Biomedical Engineering and Informatics, Luddy School of Informatics, Computing, and Engineering, as well as a professor at the Department of Orthopaedic Surgery, School of Medicine. Before joining IU, he was the Mary S. and Joseph S. Stern Jr. Chair in Musculoskeletal Research and Professor of Orthopaedic Surgery at the University of Cincinnati (UC), overseeing basic and translational orthopaedic research. Dr. Lin has been a pioneer in tissue engineering and regenerative medicine, with his innovations significantly shaping current paradigms for treating musculoskeletal disorders. These include an ongoing Department of Defense-funded Phase 1/2 clinical trial investigating the safety and efficacy of AM3101, an injectable therapeutic his team developed to promote meniscus repair and regeneration.
Before his tenure in Orthopaedic Surgery, Dr. Lin was recruited to UC in 2014 as the Dane A. and Mary Louise Miller Chair in Biomedical Engineering. His research in biofabrication produced numerous breakthroughs for congenital defect repair and skeletal tissue reconstruction, often in collaboration with Cincinnati Children’s Hospital, Procter & Gamble, Ethicon, and GE Aviation.
Dr. Lin’s research is highly translational, bridging basic science, clinical innovation, and entrepreneurship. He has secured over $9 million in competitive research funding as principal or co-principal investigator from agencies including the National Institutes of Health (NIH) and the Department of Defense (DoD). His active grants include an NIH R01 (NINDS, $2.2M) to develop a smart bioengineered patch for fetal spina bifida repair, and a DoD Congressionally Directed Medical Research Program award ($2.0M) supporting the AM3101 clinical trial. His past grants encompass multiple NIH R01 and R21 awards, institutional pilot grants, and industry partnerships, advancing regenerative strategies such as simvastatin-loaded injectable hydrogels, hybrid tracheal constructs, and 3D-printed decellularized matrix scaffolds.
Dr. Lin is also a serial entrepreneur, having co-founded Tissue Regeneration Systems, Inc., which was acquired by DePuy Synthes (Johnson & Johnson). He currently leads Amplicore Inc., a biopharmaceutical startup developing novel injectable therapies for degenerative skeletal soft tissues. His entrepreneurial and scientific contributions have been recognized with the James Russell Neff Award (2019), the Ohio Faculty Council Technology Commercialization Award (2019), and the Emerging Entrepreneurial Achievement Award (2020).